Nasal Swab Might Predict How Severe COVID Will Be
Medically reviewed by Drugs.com.
By Dennis Thompson HealthDay Reporter
WEDNESDAY, Nov. 6, 2024 -- A simple nasal swab might help doctors predict the severity of a person’s COVID infection, a new study suggests.
More than 70% of people with mild or moderate COVID develop certain antibodies in their nasal cavities that are linked to fewer symptoms, better immune response and faster recovery, researchers reported Nov. 6 in the journal Science Translational Medicine.
These are autoantibodies, or antibodies that attack the body and typically are associated with autoimmune diseases like rheumatoid arthritis, inflammatory bowel disease and psoriasis, researchers said.
“Generally, autoantibodies are associated with pathology and a negative prognosis, causing increased inflammation that would indicate more severe disease,” noted senior researcher Eliver Ghosn, a faculty member with the Emory University’s Lowance Center for Human Immunology and Emory Vaccine Center.
Previous studies of COVID patients have suggested that autoantibodies in the blood indicate a more life-threatening illness.
But those studies looked at the blood rather than in the nose, which is the actual site of infection, researchers said.
“What’s interesting about our findings is that with COVID-19, it’s the opposite. The nasal autoantibodies showed up soon after infection, targeting an important inflammatory molecule produced by the patient’s cells,” Gohsn said in an Emory news release.
“These autoantibodies latched on to the molecule, likely to prevent excessive inflammation, and faded as people recovered, suggesting the body uses them to keep things in balance,” Gohsn added.
These findings indicate that the immune response mounted in the nose against COVID differs from that mounted in the blood.
Nasal autoantibodies provide protection, while autoantibodies in the blood are linked to more severe COVID.
“The key to this puzzle was to look directly at the site of infection, in the nose, instead of the blood,” Ghosn said. “While autoantibodies in the blood were linked to bad prognosis, producing them only in the nose soon after infection is linked to efficient recovery.”
Researchers are working on a nasal swab test that could be used to predict how bad a person’s COVID infection will prove to be.
“Right now, we’re either looking at infection risk before it happens or analyzing the infection course well after recovery,” said researcher Ben Babcock, a doctoral candidate at Emory. “Imagine if we could capture the immune response in real time, right in the clinic. A just-in-time test could give physicians and patients the real-time information they need to make faster, smarter treatment decisions.”
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-07 06:00
Read more
- Rates of Anxiety, Depression Rising Among Americans, Especially the Young
- Anxiety/Depression Linked to HRQoL Losses in Seropositive RA
- Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
- Malaria Developing Resistance to Drug That Saves Children's Lives
- Stereotactic Radiosurgery Safe for Koos Grade I Vestibular Schwannomas
- McDonald's Quarter Pounder Beef Patties Not Source of E. Coli Contamination
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions